P
Paola Bordi
Researcher at University of Parma
Publications - 70
Citations - 1607
Paola Bordi is an academic researcher from University of Parma. The author has contributed to research in topics: Lung cancer & Osimertinib. The author has an hindex of 20, co-authored 61 publications receiving 1135 citations.
Papers
More filters
Journal ArticleDOI
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.
TL;DR: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR TKIs, such as gefitinib and afatinib.
Journal ArticleDOI
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
Melissa Bersanelli,Roberta Minari,Paola Bordi,Letizia Gnetti,Cecilia Bozzetti,Anna Squadrilli,Costanza Lagrasta,Lorena Bottarelli,Ganna Osipova,Enrica Capelletto,Marco Mor,Marcello Tiseo +11 more
TL;DR: A case of advanced NSCLC with coexisting primary L585R and secondary T790M EGFR mutations that acquired resistance to AZD9291 (osimertinib) due to the occurrence of the tertiary L718Q mutation is presented.
Journal ArticleDOI
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Alessio Cortellini,Rita Chiari,Biagio Ricciuti,Giulio Metro,Fabiana Perrone,Marcello Tiseo,Melissa Bersanelli,Paola Bordi,Daniele Santini,Raffaele Giusti,Antonino Grassadonia,Pietro Di Marino,N. Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Daniela Iacono,Maria Rita Migliorino,Giampiero Porzio,Katia Cannita,Corrado Ficorella,Sebastiano Buti +34 more
TL;DR: It is confirmed that irAEs are concordantly related to higher ORR, longer PFS, and longer OS with anti-PD-1 immunotherapy in patients with NSCLC.
Journal ArticleDOI
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
Marzia Del Re,Marcello Tiseo,Paola Bordi,Armida D'Incecco,Andrea Camerini,Iacopo Petrini,Maurizio Lucchesi,Alessandro Inno,Daniele Spada,Enrico Vasile,Valentina Citi,Giorgio Malpeli,Enrica Testa,Stefania Gori,Alfredo Falcone,Domenico Amoroso,Antonio Chella,Federico Cappuzzo,Andrea Ardizzoni,Aldo Scarpa,Romano Danesi +20 more
TL;DR: MUTKRAS could be an additional mechanism of escape from EGFR-TKI inhibition and cftDNA is a feasible approach to monitor the molecular development of drug resistance.
Journal ArticleDOI
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
Roberta Minari,Paola Bordi,M. Del Re,Francesco Facchinetti,Francesca Mazzoni,Fausto Barbieri,Andrea Camerini,Camilla E. Comin,Letizia Gnetti,Cinzia Azzoni,Rita Nizzoli,Beatrice Bortesi,Eleonora Rofi,Paolo Petreni,Nicoletta Campanini,Giulio Rossi,Romano Danesi,Marcello Tiseo +17 more
TL;DR: Although liquid biopsy is a relevant tool to diagnose T790M presence in NSCLC patients resistant to EGFR-TKI, in case of a low ratio T790m/activating mutation, tissue biopsy should be considered to exclude the presence of SCLC transformation and/or other concomitant resistance mechanisms.